Luiza Mansur Cerioni Silva

Luiza Mansur Cerioni Silva

Auto-generated profile, based on publicly available information

Luiza Mansur Cerioni Silva

Escola de Medicina Jundiai (FMJ), Department of Anesthesiology, Jundiai, SP, Brazil

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2026 in Brazilian Journal of Anesthesiology (English Edition)
Verified
Journal Article
Open access
FTFabio Vieira Toledo
Fabio Vieira Toledo
JMJose Fernando Amaral Meletti
Jose Fernando Amaral Meletti
LSLuiza Mansur Cerioni Silva
Luiza Mansur Cerioni Silva
NSNathalia Maria Medeiros Serra
Nathalia Maria Medeiros Serra
MMMaria Nathalia Prado Simoes Mendonça
Maria Nathalia Prado Simoes Mendonça
CPClóvis Antonio Lopes Pinto
Clóvis Antonio Lopes Pinto
Surgery remains one of the most important treatments for breast cancer. In this context, the quality of postoperative recovery has become a key concern. Adequate control of acute pain is essential to optimize patient comfort and recovery. Pregabalin may contribute to this goal by preventing central sensitization and reducing perioperative anxiety. To evaluate the effect of perioperative pregabalin versus placebo on postoperative recovery quality in patients undergoing breast cancer surgery. In this randomized controlled trial, 92 patients received either pregabalin (150 mg orally, 1 hour before surgery) or a matching placebo, both prepared in identical capsules. The primary outcome was the QoR-15 score measured preoperatively, and at 24 and 48 hours postoperatively. The 24- and 48-hour assessments were conducted via telephone. The QoR-15 is a validated instrument that assesses the quality of recovery, with total scores ranging from 0 (very poor recovery) to 150 (excellent recovery). Secondary outcomes included opioid consumption, pain scores, incidence of nausea and vomiting, and lengths of stay in the Post-Anesthesia Care Unit (PACU) and hospital. An exploratory analysis of longitudinal changes in QoR-15 scores within each group was also performed. Analyses were performed per protocol. Eighty-four patients completed the study. There were no differences in overall QoR-15 score between the groups at any of the three assessment time points (preoperative, 24h, and 48h). In the exploratory longitudinal within-group analysis, better maintenance of recovery quality was observed in the pregabalin group compared with baseline, with medians (IQR) of 138 (122.3-145), 132.5 (125.8-135.3), and 134 (131.5-136) [p = 0.006 between 24h and 48h]. In the placebo group, the medians (IQR) were 140 (128-145.3), 129 (126-134.3), and 134 (126.8-136.3) [p = 0.002 between pre and 24h; p = 0.026 between pre and 48h]. Although exploratory analysis showed a trend toward improvement within the pregabalin group, there was no significant difference in QoR-15 scores between groups.